Literature DB >> 26010460

Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.

Kirsty Bannister1, Ryan Patel, Leonor Goncalves, Louisa Townson, Anthony H Dickenson.   

Abstract

Diffuse noxious inhibitory controls (DNICs) utilize descending inhibitory controls through poorly understood brain stem pathways. The human counterpart, conditioned pain modulation, is reduced in patients with neuropathy aligned with animal data showing a loss of descending inhibitory noradrenaline controls together with a gain of 5-HT3 receptor-mediated facilitations after neuropathy. We investigated the pharmacological basis of DNIC and whether it can be restored after neuropathy. Deep dorsal horn neurons were activated by von Frey filaments applied to the hind paw, and DNIC was induced by a pinch applied to the ear in isoflurane-anaesthetized animals. Spinal nerve ligation was the model of neuropathy. Diffuse noxious inhibitory control was present in control rats but abolished after neuropathy. α2 adrenoceptor mechanisms underlie DNIC because the antagonists, yohimbine and atipamezole, markedly attenuated this descending inhibition. We restored DNIC in spinal nerve ligated animals by blocking 5-HT3 descending facilitations with the antagonist ondansetron or by enhancing norepinephrine modulation through the use of reboxetine (a norepinephrine reuptake inhibitor, NRI) or tapentadol (μ-opioid receptor agonist and NRI). Additionally, ondansetron enhanced DNIC in normal animals. Diffuse noxious inhibitory controls are reduced after peripheral nerve injury illustrating the central impact of neuropathy, leading to an imbalance in descending excitations and inhibitions. Underlying noradrenergic mechanisms explain the relationship between conditioned pain modulation and the use of tapentadol and duloxetine (a serotonin, NRI) in patients. We suggest that pharmacological strategies through manipulation of the monoamine system could be used to enhance DNIC in patients by blocking descending facilitations with ondansetron or enhancing norepinephrine inhibitions, so possibly reducing chronic pain.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26010460     DOI: 10.1097/j.pain.0000000000000240

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  51 in total

1.  Top-down control of pain.

Authors:  Lucy F Donaldson; Bridget M Lumb
Journal:  J Physiol       Date:  2017-07-01       Impact factor: 5.182

2.  An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis.

Authors:  S M Lockwood; K Bannister; A H Dickenson
Journal:  J Neurophysiol       Date:  2018-11-21       Impact factor: 2.714

Review 3.  Spinal α2 -adrenoceptors and neuropathic pain modulation; therapeutic target.

Authors:  Zahra Bahari; Gholam Hossein Meftahi
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

4.  Is tapentadol different from classical opioids? A review of the evidence.

Authors:  Richard M Langford; Roger Knaggs; Paul Farquhar-Smith; Anthony H Dickenson
Journal:  Br J Pain       Date:  2016-07-25

Review 5.  The plasticity of descending controls in pain: translational probing.

Authors:  Kirsty Bannister; A H Dickenson
Journal:  J Physiol       Date:  2017-05-26       Impact factor: 5.182

Review 6.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

Review 7.  What do monoamines do in pain modulation?

Authors:  Kirsty Bannister; Anthony H Dickenson
Journal:  Curr Opin Support Palliat Care       Date:  2016-06       Impact factor: 2.302

8.  Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans.

Authors:  Manting D Chiang; Karen Frey; Chris Lee; Evan D Kharasch; Dani Tallchief; Christopher Sawyer; Jane Blood; Hyunmoon Back; Leonid Kagan; Simon Haroutounian
Journal:  Br J Clin Pharmacol       Date:  2020-06-30       Impact factor: 4.335

Review 9.  Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing.

Authors:  Rory V Smith; Patrick Wilkins; Kirsty Bannister; Tatum M Cummins
Journal:  NPJ Parkinsons Dis       Date:  2021-03-17

10.  The Stage-Specific Plasticity of Descending Modulatory Controls in a Rodent Model of Cancer-Induced Bone Pain.

Authors:  Mateusz Wojciech Kucharczyk; Diane Derrien; Anthony Henry Dickenson; Kirsty Bannister
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.